Vir Biotechnology (VIR) Income towards Parent Company (2018 - 2026)

Vir Biotechnology has disclosed Income towards Parent Company across 9 years of filings, most recently posting -$125.7 million for Q1 2026.

• Income towards Parent Company for Q1 2026 came in at -$125.7 million, down 3.91% year-over-year; the trailing twelve-month figure through Mar 2026 was -$442.7 million (up 23.36% YoY), and the FY2025 annual result was -$438.0 million, up 16.09% from the prior year.
• Income towards Parent Company came in at -$125.7 million for Q1 2026 at Vir Biotechnology, down from -$42.9 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $518.6 million in Q1 2022 to a low of -$213.7 million in Q3 2024.
• The 5-year median for Income towards Parent Company is -$116.0 million (2023), against an average of -$69.7 million.
• Peak annual rise in Income towards Parent Company reached 407.04% in 2022, while the deepest fall reached 223.75% in 2022.
• Vir Biotechnology's Income towards Parent Company stood at -$101.6 million in 2022, then decreased by 14.14% to -$116.0 million in 2023, then advanced by 9.82% to -$104.6 million in 2024, then soared by 58.96% to -$42.9 million in 2025, then tumbled by 192.84% to -$125.7 million in 2026.
• The last three Income towards Parent Company figures came in at -$125.7 million (Q1 2026), -$42.9 million (Q4 2025), and -$163.1 million (Q3 2025), per Business Quant data.